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Abstract
Upon host infection, the human pathogenic microbe Staphylococcus aureus (S. aureus) immediately faces innate immune
reactions such as the activated complement system. Here, a novel innate immune evasion strategy of S. aureus is described.
The staphylococcal proteins surface immunoglobulin-binding protein (Sbi) and extracellular fibrinogen-binding protein
(Efb) bind C3/C3b simultaneously with plasminogen. Bound plasminogen is converted by bacterial activator staphylokinase
or by host-specific urokinase-type plasminogen activator to plasmin, which in turn leads to degradation of complement C3
and C3b. Efb and to a lesser extend Sbi enhance plasmin cleavage of C3/C3b, an effect which is explained by a
conformational change in C3/C3b induced by Sbi and Efb. Furthermore, bound plasmin also degrades C3a, which exerts
anaphylatoxic and antimicrobial activities. Thus, S. aureus Sbi and Efb comprise platforms to recruit plasmin(ogen) together
with C3 and its activation product C3b for efficient degradation of these complement components in the local microbial
environment and to protect S. aureus from host innate immune reactions.
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Introduction
Staphylococcus aureus, a persisting human pathogen, can cause a
variety of diseases including skin infections, pneumonia, endocar-
ditis, and sepsis [1,2]. Upon infection, S. aureus is immediately
recognized and targeted by innate immune responses, such as the
complement system. Activation of complement by foreign surfaces
(alternative pathway, AP), by antibodies (classical pathway, CP) or
by mannan (lectin pathway, LP) causes microbial opsonization,
leukocyte recruitment, and cell lysis. All three pathways lead to the
cleavage of C3 and subsequent formation of anaphylatoxin C3a
and opsonin C3b. C3a attracts and activates granulocytes; whereas
C3b attaches covalently to the bacterial surface, amplifies
complement activation, and thereby labels cells for phagocytosis.
Furthermore, C3b deposition leads to inflammatory reactions and
formation of the pore-forming terminal complement complex [3–
5].
S. aureus evades the complement system by targeting C3 and the
activity of C3 convertases [6]. At least three C3 binding proteins
that exert complement inhibitory functions have been identified in
S. aureus: staphylococcal immunoglobulin-binding protein (Sbi),
extracellular fibrinogen-binding molecule (Efb), and the Efb
homologue protein Ehp [7–9]. Sbi blocks the AP by induction
of C3 consumption [10,11] and Efb inhibits binding of factor B to
C3b and blocks the C3 and C5 convertases [12,13]. The
interaction of Sbi or Efb with the thioester-containing domain
(TED) in C3 induces a conformational change in the C3 molecule
[11,14]. In a tripartite complex with the human complement
regulator factor H, C3 [14] or C3b [15] is degraded by factor I.
Sbi binds C3 via its structural domains 3 and 4 [11,15], which
harbor a three-helix bundle motif and are structurally related to
the C3 binding domain in Efb [14,16].
Previous work demonstrated that S. aureus binds the human
plasma protein plasminogen (PLG) to its surface and expresses a
plasminogen activator, staphylokinase (SAK), that converts plas-
minogen to the serine protease plasmin (PL) [17,18]. However, it
was unclear how S. aureus binds plasminogen to target the host C3
molecule for complement evasion. Plasmin controls several
processes such as fibrinolysis, wound healing and tissue remodel-
ing. Thus pathogenic microbes often exploit the proteolytic
activity of plasmin to degrade components of the extracellular
matrix (ECM), as well as fibrinogen for dissemination in the host
[19,20]. Beside fibrinolytic activity, plasmin can cleave native C3
leading to the formation of the anaphylatoxin C3a [21–24] and
C3b, which is subsequently degraded and inactivated to iC3b and
C3c [25–28].
This report demonstrates that plasminogen, which is bound by
the staphylococcal proteins Sbi and Efb, is converted to plasmin by
S. aureus secreted SAK. Bound plasmin subsequently cleaves C3
and C3b that are simultaneously bound by Sbi and Efb. This
proteolytic process are enhanced by the conformational changes
Efb and presumably Sbi induce in C3 and C3b. In addition,
plasmin was shown to degrade C3a that harbors chemoattractant
and antimicrobial activities. Thus, recruitment and activation of
plasminogen by S. aureus is highly coordinated to maximize
complement inhibition at the level of C3.
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Bacterial strains
S. aureus strain Newman was cultured on blood agar (Invitrogen)
or in Luria broth at 37uC.
Cloning, Expression and Purification of proteins
Recombinant Sbi 1–4 (subsequently referred to as Sbi) and Sbi 3–4
were expressed as previously described [15]. Efb and Efb-C were
expressed using the E.coli pET200/D-TOPO expression system
(Invitrogen) and Efb forw: CACCTCTTTATTAACATTAGCGG-
CAATAG and Efb rev: TTATTTAACTAATCCTTGTTTTAA-
TACA, or Efb-C forw: CACCACTGATGCAACTATTAAAA and
Efb-C rev: TTATTTAACTAATCCTTGTTTTAATACA primers
for amplification. Sbi 1–2 and SAK were cloned into E.coli pET101/
D-TOPO expression vector (Invitrogen) using Sbi 1–2 forw:
CACCATGACAACTCAAAACAACTACGTAAC and Sbi 1–2
rev: ATTTTGACGTTCTTTAGCTTTAGAAGATTGTACTG,
or SAK forw: CACCATGCTCAAAAGAGGTTTATTATTTT-
TAAC and SAK rev: TTTCTTTTCTATAATAACCTTTG-
TAATTAAGTTG primers. Expression and purification was
performed according the user’s manual. Affinity chromatography
with Ni-NTA-Agarose (GE Healthcare) was used as previously
described [15]. CRASP-5 of B. burgdorferi was expressed and purified
as previously described [29] [29] [29] [29]. Plasma purified
plasminogen (Haemochrom Diagnostica) was biotinylated with
Sulfo-NHS-LC-Biotin (Thermo Scientific) according to manufactur-
er’s instructions. However a 10 fold molar excess of biotin was used.
Unbound biotin was removed by Zeba
TM Desalt Spin Columns
(Pierce).
Ligand blot
Staphylococcal proteins were separated by SDS-PAGE and
transferred onto a nitrocellulose membrane. After blocking with
1% BSA, 4% milk powder, 0.1% Tween20 in PBS for 1 h at RT,
the membranes were incubated with 1 mg/ml biotin-coupled
plasminogen (PLGb) or C3 (CompTech) overnight at 4uC. Bound
PLGb was detected with Streptavidin-Peroxidase (1:1000; Sigma),
C3 with anti-C3-Fab-HRP (1:1000; Protos Immunoresearch), and
to assess IgG-binding, rabbit anti-goat-HRP (1:1000; DAKO) was
applied. All blots were developed using the ECL-substrate
(AppliChem).
Enzyme linked Immunosorbent Assay (ELISA)
Bacterial proteins were immobilized (equimolar) onto a
microtiter plate (Maxisorb, Nunc) blocked with 0.4% gelatin in
DPBS for 2 h at 37uC, PLGb was added for 1.5 h at 37uC, and
bound proteins were detected with Streptavidin-Peroxidase
(1:1000) for 1 h at RT. The reaction was developed with TMB
(KEM EM TEC), stopped by addition of 0.25 M H2SO4 and
measured at 450 nm.
For dose-dependent binding of PLG to Sbi 3–4/Efb-C, 5 mg/ml
Sbi 3–4 or Efb-C were immobilized to a microtiter plate, blocked
with Blocking Solution I (AppliChem) for 2 h at 37uC and 25–
800 nM PLG were added for 2 h at 37uC. Bound proteins were
Figure 1. Plasminogen is recruited by Sbi and Efb. (A) Plasminogen bound to Sbi and Efb (lane 1 and 2). The accuracy of the recombinant
staphylococcal proteins was confirmed as both, Sbi and Efb, bound to C3 (lane 3 and 4) and Sbi also bound IgG. Recombinant Sbi or Efb was
separated by SDS-PAGE and either blotted to a membrane (lane 1–6) or silver stained (lane 7–8). Membranes were incubated with biotinylated PLG
(PLGb), C3, or HRP- coupled IgG and bound proteins were detected as indicated. (B) Binding of plasminogen to Sbi or Efb was confirmed by ELISA.
Bacterial proteins (equimolar) were immobilized and PLGb was applied and detected using streptavidin-HRP. Plasminogen binding to Sbi and Efb was
comparable to plasminogen binding to the borrelial protein CRASP-5. Plasminogen did not bind to HSA or the plate (buffer). Data represent mean
values 6 standard deviations from three independent experiments. (C) Plasminogen was recruited to Sbi and Efb. Non-labeled plasminogen was
applied to immobilized bacterial proteins. Bound proteins were eluted, separated by SDS-PAGE and plasminogen (92 kDa) was detected by Western
blot analysis. CRASP-5 bound plasminogen in contrast to HSA and buffer. A representative experiment out of three is shown.
doi:10.1371/journal.pone.0047638.g001
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PLOS ONE | www.plosone.org 2 October 2012 | Volume 7 | Issue 10 | e47638Figure 2. Characterization of the Plasminogen interactions with Sbi and Efb-C. (A+B) Plasminogen (PLG) bound to the fragments 3–4 of Sbi
(A) and the C-terminus of Efb (B). Sbi 3–4 or Efb-C was immobilized and increasing amounts of plasminogen were added. Bound plasminogen was
detected with specific antisera. Plasminogen concentrations showing saturated binding are marked by arrows. (C+D) Plasminogen (solid lines)
associated with Sbi 3–4 (C) or Efb-C (D) was determined by surface plasmon resonance. Sbi 3–4 or Efb-C was immobilized and plasminogen was
applied in fluid phase. Binding of plasminogen to Sbi 3–4 or Efb-C was inhibited by eACA (dashed line). (E+F) Plasminogen (black columns) and C3
(grey columns) bound simultaneously to Sbi 3–4 (E) and Efb-C (F). Sbi 3–4 or Efb-C was immobilized and C3 and plasminogen were added either
alone or together (200 nM C3:200 nM PLG =1:1 for EfbC, 200 nM C3:400 nM PLG=1:2 for Sbi3-4). Representative experiments out of three
independent experiments are shown.
doi:10.1371/journal.pone.0047638.g002
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Down Buffer (AppliChem) and anti-goat HRP (1:2000). In
competition assays Sbi 3–4 or Efb-C were immobilized and
incubated with concentrations of C3 (200 nM) and plasminogen
(200 for Efb-C and 400 nM for Sbi 3–4) that saturate binding sites.
C3 binding was detected using polyclonal anti-C3-antibody
(CompTech; 1:1000) and plasminogen binding with polyclonal
plasminogen-antiserum.
Combined ELISA-Western blot analysis (CEWA)
Combined ELISA-Western blot analysis was performed ac-
cording to Haupt et al [15]. Briefly, equimolar amounts of Sbi,
Efb, CRASP-5, and HSA were immobilized onto a microtiter
plate. After blocking with gelatin, 50 nM plasma purified
plasminogen was added and incubated overnight at 4uC. Bound
plasminogen was eluted using SDS buffer, separated by SDS-
PAGE, and analyzed by Western blotting using plasminogen
antiserum (1:2000). Borrelia burgdorferi CRASP-5 protein was
included as a positive control and HSA (Cleveland, Ohio) as a
negative control.
Surface plasmon resonance (SPR)
Binding of plasminogen to Sbi 3–4 or Efb-C was analyzed by
surface plasmon resonance (Biacore 3000, AB) at 25uC in 150 mM
PBS. Sbi 3–4 or Efb-C was immobilized on a CMD 500 M sensor
chip (Xantec) by standard amino coupling chemistry following the
manufacturer’s protocol. Plasminogen (400 nM) was injected at a
constant flow rate of 5 ml/min.
Plasmin activity assay
Plasmin activation was determined by hydrolysis of the PL-
specific substrate S-2251(D-valyl-leucyl-lysine-r-nitroanilide dihy-
drochloride; Haemochrom Diagnostica). Therefore Sbi, Efb,
CRASP-5, or HSA were immobilized (equimolar) onto a
microtiter plate. After blocking with 0.4% gelatin, 0.2 mM
plasminogen was incubated at 4uC overnight. Following washing
with PBS +0.05% Tween20, uPa (Haemochrom Diagnostica;
0.08 mg/ml) or recombinant SAK (1 mg/ml) were added together
with the chromogenic substrate S-2251 dissolved in reaction buffer
(64 mM Tris, 350 mM NaCl, 0.01% Triton-X; pH 7.5). PL
activity was recorded at 4 h intervals at 405 nm (SpektraMax 190;
Molecular Devices).
Antimicrobial assay
C3a (1 mM) (CompTech) was incubated with S. aureus (3610
4)i n
10 mM Tris-HCL with 5 mM Glucose (pH 7.4) with or without
5 mg PLG and/or 1 mg SAK at 37uC for 2 h with agitation.
Bacteria were diluted 1:5, 20 ml were plated onto a LB plate in
Figure 3. Plasminogen bound to Sbi or Efb is converted to plasmin. (A) Plasmin (PL) bound to Sbi, Efb, and to the borrelial CRASP-5
converted a chromogenic substrate as followed by measuring absorbance at 405 nm after 24 h. Equimolar amounts of bacterial proteins were
immobilized and incubated with plasminogen (PLG). After washing, the activator uPA was applied together with the chromogenic substrate S-2251.
Human serum albumin (HSA) had no effect. (B+C) Plasmin generation of plasminogen bound to Sbi (B) and Efb (C) by uPa or staphylokinase (SAK).
The plasmin activators uPa and SAK or no activator (w/o) were applied to plasminogen bound to Sbi or Efb together with the chromogenic substrate.
Conversion of the chromogenic substrate was determined at various time points. Data represent mean values 6 standard deviations from three
independent experiments.
doi:10.1371/journal.pone.0047638.g003
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supernatant was separated by SDS-PAGE and analyzed by
Western blotting with polyclonal anti-C3a antibody (1:1000;
CompTech).
C3/C3b degradation by Sbi/Efb bound PL
Plasminogen (0.2 mM) together with either 0.04 mMC 3o r
0.04 mM C3b were incubated with immobilized Sbi, Efb, CRASP-
5, or HSA overnight at 4uC. After extensive washing 0.5 mM SAK
or 0.06 mM uPa were added for 3 h at 37uC. Samples were
reduced with Roti-Load for 5 min at 95uC, separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. C3/C3b
and their cleavage products were detected with HRP-conjugated
anti-C3-Fab antiserum (1:1000).
C3/C3b degradation by plasmin in fluid phase
0.04 mM C3 or C3b with either 0.15 mM plasminogen plus
0.04 mM uPa or 0.2 mM PLG plus 0.5 mM SAK were incubated in
the absence or presence of Sbi, Efb, CRASP-5, or HSA (each
1 mM) for 3 h at 37uC. Additionally the same assays were
performed using 0.2 or 2 mM of the fragments Sbi 1–2, Sbi 3–4,
and Efb-C. Samples were analyzed as described above.
C3 ELISA
C3 (0.04 mM) was immobilized to a microtiter plate at room
temperature, after blocking with 0.4 % gelatin, 0.15 mM
plasminogen with 0.04 mM uPa or 0.2 mM plasminogen with
0.5 mM SAK incubated for 3 h at 37uC. Sbi 3–4, Efb-C, CRASP-
5, or HSA (each1 mM) were added in the presence or absence of
plasmin. After extensive washing bound C3 was detected using
C3a antiserum supplemented with 15 mg/ml aprotinin (to inhibit
plasmin) and HRP-coupled antiserum at 4uC.
C3b deposition assay
S. aureus was heat inactivated for 15 min at 72uC and incubated
with 5% serum in HEPES buffer (20 mM Hepes, 140 mM NaCl2,
5 mM CaCl2, 25 mM MgCl2; pH 7.4) for 20 min at 37uC. Then
bacteria were incubated with Sbi 1–2, Sbi 3–4, Efb-C, or HSA
(each 2 mM) in the absence or presence of 0.15 mM plasmin
(Calbiochem) for 2 h at 37uC. Supernatants were reduced with
Figure 4. Plasmin complexed with C3(b) and Sbi or Efb degrades C3 and C3b within the complex. Plasmin degraded C3/C3b within the
Sbi:plasmin:C3/C3b or Efb:plasmin:C3/C3b complexes (lane 1 and 4) and C3/C3b cleavage products appeared (marked with arrows). Bacterial proteins
were immobilized (equimolar) and plasminogen was added together with C3 (A) or C3b (B). The activator SAK was applied and C3/C3b cleavage was
followed by Western blot analysis using anti-C3-HRP (Fab). The mobility of the a (a) and b chains of C3/C3b and the cleavage products are indicated
by arrows. CRASP-5 and HSA had no effect on cleavage (lane 7 and 8). Data shown are representative of three independent experiments. (C)
Proposed schematic model of the C3 cleavage products generated by plasmin modified after [25,32]. The C3 dg cleavage product is not recognized
by the C3-antibodies used in this study.
doi:10.1371/journal.pone.0047638.g004
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blotting using anti-C3-HRP. Bacteria surface-bound C3b was
measured by flow cytometry with FITC-labeled anti-C3-Fab
(Protos Immunoresearch).
Statistical analysis
Significant differences between two groups were analyzed by the
unpaired Student’s t-test. Values of *p,0.05, **p,0.01,
***p,0.001 were considered as statistically significant.
Results
Plasminogen binds to Sbi and Efb
Sbi and Efb are C3 and C3b binding proteins. In order to
investigate whether Sbi and Efb also recruit plasminogen, binding
of plasminogen to recombinant Sbi and Efb was tested. The
accuracy of recombinant Sbi and Efb was confirmed as both
molecules showed binding to C3 and in addition Sbi bound to IgG
(Fig. 1). Immobilized Sbi or Efb was incubated with biotin-labeled
plasminogen (PLGb) and binding was assayed by ELISA.
Plasminogen bound to both staphylococcal proteins Sbi and Efb.
Plasminogen binding to Sbi and Efb was similar to the previously
identified plasminogen ligand CRASP-5 of Borrelia burgdorferi
[30,31], (Fig. 1A+B). To exclude non-specific binding of plasmin-
ogen via its biotin-label, binding of unlabeled plasminogen to Sbi
or Efb was tested using a combined ELISA-Western blot assay.
Plasminogen was added to immobilized Sbi or Efb, washed, and
all surface bound proteins were separated by SDS PAGE and
immunoblotted for the detection of plasminogen. Also free
plasminogen bound to Sbi, Efb, and CRASP-5 (Fig. 1C).
Characterization of the PLG:Sbi and PLG:Efb interactions
To determine the Sbi and Efb domains responsible for
interaction with plasminogen, plasminogen binding to the
structurally related domains Sbi 3–4 and Efb-C in Sbi and Efb,
respectively, was assayed. Plasminogen added to the immobilized
Figure 5. Plasmin mediated cleavage of C3 is enhanced by Sbi and Efb. (A) In the presence of Sbi and Efb (lane 1 and 2) the C3 a-chain
decreased and C3 cleavage products (indicated by arrows) appeared. CRASP-5 did not show this effect. C3 was incubated with SAK-activated plasmin
(PLSAK) in the presence of Sbi, Efb, CRASP-5, or HSA. Samples were separated by SDS-PAGE and C3 cleavage products were visualized using Western
blot analysis. (B) A similar assay was performed with uPa as activator and this time the fragments Sbi 1–2, Sbi 3–4, and Efb-C were assayed. Sbi 3–4
(lane 5 and 6) and Efb-C (lane 8 and 9) enhanced the plasmin mediated C3 cleavage as seen by the appearance of small cleavage products. The IgG-
binding Sbi 1–2 (mobility of 17 kDa) did not affect the C3 cleavage pattern (lane 2 and 3). Polyclonal C3 antiserum was used for detection. (C) In the
presence of Sbi 3–4 and Efb-C the plasmin mediated C3 proteolysis was enhanced as measured by ELISA. C3 was immobilized and plasmin (activated
by uPa or SAK) together with Sbi 3–4 or Efb-C were added. C3 deposition was detected after 3 h with C3a antiserum. CRASP-5 and HSA did not
influence plasmin cleavage of C3. (D) Sbi 3–4 and Efb-C significantly enhanced C3 degradation by plasmin in a dose dependent manner. The C3
amount after incubation with plasmin was set to 100%. Data in C and D are mean values of three independent experiments; error bars indicate
standard deviations. *p,0.05; **p,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0047638.g005
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(Fig. 2B) in a dose-dependent manner. These binding interactions
were also followed in real time by using surface plasmon
resonance. Plasminogen added in fluid phase bound to immobi-
lized Sbi 3–4 or Efb-C, confirming the interaction between
plasminogen and these specific Sbi and Efb domains. To
investigate whether plasminogen binding to Sbi and Efb occurs
via lysine residues, eACA, a lysine analog which blocks lysine
residues, was used in binding assays. eACA interfered with
plasminogen binding to both Sbi 3–4 and Efb-C, demonstrating
that lysine residues are involved in the interactions of these
bacterial proteins with plasminogen.
To determine whether plasminogen and C3 bind simultaneous-
ly to Sbi and Efb, each plasma protein was added to immobilized
Sbi 3–4 or Efb-C using concentrations of plasminogen (400 nM
for Sbi 3–4 and 200 nM for EfbC) which saturate all binding sites.
Plasminogen and C3 binding were measured in parallel. C3
binding to Sbi 3–4 and Efb-C, as well as plasminogen binding to
Sbi 3–4 remained unchanged. Plasminogen binding to Efb-C was
slightly reduced in the presence of C3 (Fig. 2E and 2F). The data
indicate that plasminogen and C3 bind simultaneously to both
staphylococcal molecules.
Plasminogen bound to Sbi or Efb is activated to plasmin
To exert proteolytic activity, plasminogen needs conversion to
plasmin by an activator. To proof whether plasminogen bound to
Sbi or Efb is converted to plasmin. Plasminogen was bound to
immobilized Sbi or Efb and treated with the human activator uPa.
Plasmin generation was followed by cleavage of a plasmin-specific
chromogenic substrate. Plasminogen-bound Sbi or Efb was
activated by uPa to plasmin, as seen by the increased conversion
of the substrate S-2251. Similarly, plasminogen bound to CRASP-
5 was activated to the protease plasmin (Fig. 3A).
SAK is known to activate plasminogen via a non-proteolytic
mechanism. To determine whether SAK is also able to activate
Sbi- or Efb-bound plasminogen SAK was used in similar
experiments instead of uPa. Also SAK activated plasminogen
bound to Sbi or Efb, and the resulting plasmin cleaved the
chromogenic substrate (Fig. 3B and C). In summary, plasminogen
bound to Sbi and Efb is activated by both staphylococcal and
human activators to form active plasmin.
Plasmin bound to Sbi or Efb degrades C3 and C3b
After plasmin(ogen) was shown to form complexes with C3 and
Sbi or Efb, the plasmin activity was assayed to cleave complexed
C3. Plasminogen was bound together with C3 to immobilized Sbi
or Efb and activated by the addition of SAK. C3 degradation was
Figure 6. Plasmin cleavage of C3b is enhanced by Sbi and Efb. (A) Sbi 3–4 (lane 5–6) and Efb-C (lane 8–9) enhanced cleavage of C3b by
plasmin, as seen by the accumulation of C3b cleavage products. Sbi 1–2 did not influence C3b degradation (lane 2–3). C3b was cleaved by plasmin in
the presence of Sbi 1–2, Sbi 3–4, and Efb-C. (B+C) Sbi 3–4 and Efb-C enhanced the anti-opsonic activity of plasmin. C3b was deposited on S. aureus
and Sbi 1–2, Sbi 3–4, Efb-C, or HSA was incubated in the absence or presence of plasmin. Remaining C3b fragments on S. aureus were measured by
flow-cytometry. The C3b amount in the absence of plasmin was set to 100%. Data represent mean values 6 standard deviations of five independent
experiments. *p,0.05. (C) In parallel the supernatants were separated by SDS-PAGE and analyzed by Western blotting using anti-C3-HRP (Fab). Sbi 1–
2 did not influence the amount of C3b-fragments after plasmin degradation (lane 1). Sbi 3–4 (lane 2) and Efb-C (lane 4) increased the plasmin
degradation and more C3b cleavage products were detected.
doi:10.1371/journal.pone.0047638.g006
Immune Evasion of Staphylococcus aureus
PLOS ONE | www.plosone.org 7 October 2012 | Volume 7 | Issue 10 | e47638investigated by separating the reaction mixture by SDS-PAGE
and Western blot analysis using anti-C3 Fab’-fragments. Multiple
C3-degradation products with mobilities of 115, 87, 68, 40, and
27 kDa were generated indicating that Sbi- or Efb-bound
plasminogen was activated by SAK to plasmin which subsequently
cleaved bound C3 (Fig. 4A). In a similar assay performed with
C3b, cleavage products with mobilities of 87, 68, 40, and 27 kDa
appeared and demonstrated that complexed plasmin also degrad-
ed C3b (Fig. 4B). When CRASP-5 or HSA was used in these
assays, instead of Sbi or Efb, no cleavage of C3 was observed
which is explained by the fact that CRASP-5 and HSA do not
acquire plasmin together with C3/C3b. Thus, plasmin complexed
together with C3/C3b and Sbi or Efb degrades the complement
proteins C3 and C3b.
C3 degradation by plasmin is enhanced by Sbi and Efb
Upon binding, Efb changes the structural conformation of C3,
leading to an increased susceptibility of C3 to degradation by
trypsin [14]. To analyze whether C3 degradation by plasmin is
also modulated by Sbi or Efb, C3 proteolysis by plasmin was
compared in the presence or absence of Sbi or Efb. C3
degradation by plasmin was enhanced by both staphylococcal
proteins, as demonstrated by the appearance of additional C3
cleavage products in Western blot analysis using anti-C3 Fab’-
fragments for protein detection (Fig. 5A). In the presence of Sbi,
C3 cleavage products with mobilities of 114 kDa (a’), 68 kDa, and
weakly 40 kDa appeared and with Efb, degradation products with
mobilities of 68, 40, and 27 kDa were detected. By contrast,
proteolytic cleavage of C3 by plasmin was not affected after
addition of CRASP-5 or HSA. To localize the Sbi and Efb
domains responsible for the degradation-enhancing activities,
fragments Sbi1-2, Sbi 3–4, and Efb-C were investigated in the
same assay. C3 cleavage by plasmin was enhanced in the presence
of Sbi 3–4 and Efb-C, but no enhancement was observed in the
presence of Sbi 1–2 (Fig. 5B). To confirm these results, C3
proteolysis was also examined using ELISA. C3 was immobilized
on a microtiter plate and plasmin (generated by uPa or SAK) was
added together with the bacterial proteins or with HSA. After
incubation, the plate was washed and the amount of bound C3
was determined. Smaller amounts of C3 were detected in reactions
containing plasmin than that of those containing plasminogen.
The plasmin-dependent reduction of C3 deposition was enhanced
by the addition of Sbi 3–4 and especially Efb-C to the reaction
mixture, but not by the addition of CRASP-5 or HSA (Fig. 5C).
This enhancement by Sbi 3–4 or Efb-C was more clearly
demonstrated by using an assay in which increasing amounts of
the bacterial proteins were used (Fig. 5D). The results indicate that
plasmin cleaves C3, and that the staphylococcal proteins Sbi or
Efb enhance the cleavage by plasmin. The two domains
responsible for the degradation-enhancing effect were fragments
Sbi 3–4 and Efb-C, each of which contains a three-helix bundle
motif.
C3b degradation by plasmin is also enhanced by Sbi and
Efb
Having shown that plasmin cleaves C3 more efficiently in the
presence of Sbi or Efb, the same effect was analyzed for C3b.
Plasmin-mediated C3b degradation was assayed using the deletion
fragments Sbi 1–2, Sbi 3–4, or Efb-C, in the same assay as
described for C3. The C3b degradation by plasmin was enhanced
in the presence of Sbi 3–4 or Efb-C, as shown by the increase in
C3b degradation products (Fig. 6A). However, the addition of Sbi
1–2 showed no enhanced degradative effect. To investigate
whether Sbi and Efb also enhance plasmin activity on the
bacterial surface, S. aureus was incubated with human serum to
allow complement-mediated C3b deposition. The C3b-coated
bacteria were then washed, incubated with plasmin plus Sbi 3–4 or
Efb-C, and C3b deposition was analyzed by flow cytometry.
Plasmin substantially reduced the C3b opsonization of S. aureus by
about 37%. In the presence of Sbi 3–4, C3b deposition was further
decreased to 50%; and in the presence of Efb-C, to 38% (Fig. 6B).
In parallel analyses, supernatants containing the C3b degradation
products were assessed by SDS-PAGE and Western blotting. C3b
cleavage products with mobilities of 41 and 27 kDa were identified
in the supernatants of those samples containing C3b-opsonized S.
aureus treated with plasmin (Fig. 6C). Again C3b degradation was
enhanced when plasmin cleaved surface-bound C3b in the
presence of Sbi 3–4 and especially Efb-C (indicated by arrows),
and the presence of Sbi 1–2 showed no effect. These results
demonstrate that C3b degradation by plasmin is accelerated by
interaction with the staphylococcal proteins Sbi and Efb on the
bacterial surface.
Plasmin degrades C3a
Plasmin cleaves C3 and generates C3a [23,24] and degrades
C3b and thereby inactivates the C3b molecule for complement
C3b amplification [25,28,32]. As C3a exhibits antimicrobial
activity [33,34] and thus can kill S. aureus, we investigated whether
S. aureus recruited plasmin also degrades C3a. Therefore, S. aureus
was treated with C3a alone or with C3a together with plasmin
activated by SAK. The supernatants were analyzed by SDS-
Figure 7. Plasmin degrades C3a. (A) C3a was completely degraded
by plasmin; plasminogen had a weak degrading effect. S. aureus was
incubated with C3a in the presence of plasmin (PLG+SAK) (lane 4) or
plasminogen alone (lane 6). The supernatants were analyzed by SDS-
PAGE and Western blot analysis. (B) Plasmin increased the survival of S.
aureus to 85% and plasminogen alone to 50%. In parallel S. aureus
treated with C3a and or plasmin(ogen) was cultivated overnight on LB
agar plates. CFUs were counted and the survival without C3a was set to
100% (white columns). Data represent mean values 6 standard
deviations from three independent experiments. ***p,0.001.
doi:10.1371/journal.pone.0047638.g007
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completely degraded C3a, as demonstrated by the absence of
detectable levels of C3a (Fig. 7A). When plasminogen was added
without SAK to S. aureus, the amount of C3a was decreased, which
is explained by synthesis and secretion of SAK by S. aureus during
incubation time and subsequent activation of plasminogen to
plasmin. In parallel, C3a antimicrobial activity against S. aureus
was analyzed in survival assays. C3a added to growing S. aureus
killed the bacteria, but in the presence of C3a and plasmin
(PLG+SAK) 85% of S. aureus survived. Plasminogen added without
SAK resulted in 50% survival of the bacteria, and addition of SAK
without plasminogen had no effect on the bacteria (Fig. 7B). Thus,
we conclude that plasmin inhibits the bactericidal activity of C3a
by degradation of the C3a molecule.
Discussion
Presented here is a novel complement evasion strategy
employed by S. aureus. Human plasminogen and C3/C3b are
simultaneously bound by the microbial proteins Sbi and Efb.
Recruited plasminogen remains accessible for the human activator
uPa or the bacterial activator SAK for conversion to active
plasmin. Plasmin bound to Sbi and Efb degrades and inactivates
C3 and C3b. This degradation is enhanced by conformational
changes exerted by Efb and to a lesser extent by Sbi on both,
bound-C3 and bound-C3b. Moreover, we show that plasmin
degrades C3a, and thus inactivates the antimicrobial activity of
C3a. Consequently, Sbi and Efb-recruited plasmin inhibits
complement cascade progression, opsonization, antimicrobial
activities, and inflammatory reactions.
The importance of the complement system in defense against S.
aureus infections is reflected by the multiple strategies this human
pathogen has developed to circumvent the host complement
attack. Thereby, S. aureus preferentially targets the central
complement component C3 to inhibit the auto-amplification loop
of the alternative pathway [7,35]. One of these strategies is the
expression of small proteins that bind the C3 convertase, like
SCIN [36,37], or C3/C3b such as Efb [38,39] and Sbi [11,15].
Additionally, S. aureus recruits complement regulators from human
plasma like factor H that acts as cofactor for the serine protease
factor I to cleave C3b [15]. Here, we show that plasminogen is
recruited by Sbi and Efb. To date, three staphylococcal
plasminogen binding proteins have been described: inosine 59-
monophosphate, a-enolase, and ribonucleotide reductase [17].
However, in contrast to these plasminogen ligands, Sbi and Efb
bind C3/C3b in addition to plasminogen. Plasminogen-binding is
mediated by the domains Sbi 3–4 in Sbi and Efb-C in Efb.
Although the sequence identity between Sbi 3–4 and Efb-C is
rather low (only 19%), both fragments contain a three-helix
bundle motif [16], in which amino acids of the a2-helixes
contribute to C3d binding [10,12]. Plasminogen and C3 bind
simultaneously to Sbi 3–4 or Efb-C and are located closely to each
other, which results in accelerated degradation of C3/C3b, once
plasminogen is converted to plasmin. The C3/C3b degradation-
enhancing activity of Efb-C is more pronounced as compared to
Sbi 3–4. This difference is likely based on the higher binding
affinity of C3d to Efb than Sbi (KD [Efb-C:C3d] =0.8 nM, KD
[Sbi 3–4:C3d] =1.4 mM) [11,14].
Plasmin cleaves C3b at several sites and generates C3c and C3d
[25–28]. The interactions of plasminogen with both staphylococ-
cal proteins Sbi or Efb depend on lysine residues. This is the same
method of plasminogen binding observed in other microbial
proteins such as PE from H. influenzae [27], CRASP-1 to -5 from B.
burgdoferi [30,31], Pra1 [40] and Gpm1 from C. albicans [41], and
indicates a similar binding strategy, which ensures activation of
plasminogen to plasmin for tissue evasion and complement escape.
Complexed with C3 and Sbi or Efb, plasminogen remains
accessible for the staphylococcal activator SAK and the human
activator uPa to be converted to plasmin. More than 67% of S.
aureus strains express the sak gene and produce the non-proteolytic
staphylokinase [42]. In addition, the pathogen can enhance uPa
production in mammalian cells [43] or activate conversion of pro-
uPa to uPa by metalloprotease aureolysin [44] to generate
plasmin. Plasmin-mediated C3b degradation is accelerated by
Sbi or Efb. These functions are mediated by the C3 binding
domains Sbi 3–4 and Efb-C, and concur with studies showing that
Efb-C-binding to C3 and C3b leads to a conformational change in
C3 which enhances proteolytic cleavage of C3 by trypsin and
factor I [14]. Thus, a similar effect of Efb-C on C3 for plasmin
degradation is anticipated.
Plasmin has also been described as a complement activator,
because it cleaves C3 to C3a and C3b [21–24]. However, as
shown here and in previous studies, plasmin further degrades C3b
and demonstrates anti-opsonic as well as complement–inhibitory
activity [25–28]. Here, we show for the first time that purified C3a
is also degraded by plasmin, and that in such cases, antimicrobial
activities against S. aureus are decreased. These results are in
accordance with those of Amara et al, who observed that while
plasmin generates C3a, the C3a amount decreased when plasmin
concentrations increased [24]. Thus, binding of plasmin by S.
aureus helps the pathogen inactivate host antimicrobial activities
and obviously represents a further survival strategy.
The powerful inhibitory effect of acquired plasmin(ogen) against
several immune defense mechanisms apparently explains why
many pathogenic microbes attach human plasminogen to their
surface and activate plasminogen to plasmin. S. aureus is
remarkably effective, using several plasmin activation pathways
and expressing at least five plasminogen binding proteins. Among
these proteins Sbi and Efb act like an amplifier of plasmin-
mediated C3 cleavage to reduce local complement activity.
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